Literature DB >> 25484108

Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.

Laia Gifre1, Joan Vidal2, Josep L Carrasco3, Xavier Filella4, Silvia Ruiz-Gaspà5, Africa Muxi6, Enric Portell2, Ana Monegal1, Nuria Guañabens1,5, Pilar Peris1,5.   

Abstract

Spinal cord injury (SCI) has been associated with a marked increase in bone loss and bone remodeling, especially short-term after injury. The absence of mechanical load, mediated by osteocyte mechanosensory function, seems to be a causative factor related to bone loss in this condition. However, the pathogenesis and clinical management of this process remain unclear. Therefore, the aim of the study was to analyze the effect of recent SCI on the Wnt pathway antagonists, sclerostin and Dickkopf (Dkk-1), and their relationship with bone turnover and bone mineral density (BMD) evolution. Forty-two patients (aged 35 ± 14yrs) with a recent (<6months) complete SCI were prospectively included. Sclerostin and Dkk-1, bone turnover markers (bone formation: PINP, bone ALP; resorption: sCTx) and BMD (lumbar spine, proximal femur, total body and lower extremities [DXA]) were assessed at baseline and at 6 and 12 months. The results were compared with a healthy control group. 22/42 patients completed the 12-month follow-up. At baseline, SCI patients showed a marked increase in bone markers (PINP and sCTx), remaining significantly increased at up to 6 months of follow-up. Additionally, they presented significantly increased Dkk-1 values throughout the study, whereas sclerostin values did not significantly change. BMD markedly decreased at the proximal femur (-20.2 ± 5.4%, p < 0.01), total body (-5.7 ± 2.2%, p = 0.02) and lower extremities (-13.1 ± 4.5%, p = 0.01) at 12 months. Consequently, 59% of patients developed densitometric osteoporosis at 12 months. Patients with higher Dkk-1 values (>58 pmol/L) at baseline showed higher sublesional BMD loss. In conclusion, this study shows that short-term after SCI there is a marked increase in bone turnover and bone loss, the latter associated with an increase in Dkk-1 serum levels. The persistence of increased levels of this Wnt antagonist throughout the study and their relationship with the magnitude of bone loss suggests a contributory role of this mediator in this process.
© 2015 American Society for Bone and Mineral Research.

Entities:  

Keywords:  DKK-1; OSTEOPOROSIS; SCLEROSTIN; SPINAL CORD INJURY; WNT SIGNALING

Mesh:

Substances:

Year:  2015        PMID: 25484108     DOI: 10.1002/jbmr.2423

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  11 in total

1.  Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.

Authors:  L Gifre; J Vidal; J L Carrasco; A Muxi; E Portell; A Monegal; N Guañabens; P Peris
Journal:  Osteoporos Int       Date:  2015-05-05       Impact factor: 4.507

2.  Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.

Authors:  L Gifre; J Vidal; J L Carrasco; A Muxi; E Portell; A Monegal; N Guañabens; P Peris
Journal:  Osteoporos Int       Date:  2015-09-30       Impact factor: 4.507

3.  Treatment with hydrogen sulfide attenuates sublesional skeletal deterioration following motor complete spinal cord injury in rats.

Authors:  X Yang; D Hao; H Zhang; B Liu; M Yang; B He
Journal:  Osteoporos Int       Date:  2016-09-03       Impact factor: 4.507

4.  Analysis of the evolution of cortical and trabecular bone compartments in the proximal femur after spinal cord injury by 3D-DXA.

Authors:  L Gifre; L Humbert; A Muxi; L Del Rio; J Vidal; E Portell; A Monegal; N Guañabens; P Peris
Journal:  Osteoporos Int       Date:  2017-10-17       Impact factor: 4.507

5.  Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.

Authors:  L Gifre; S Ruiz-Gaspà; J L Carrasco; E Portell; J Vidal; A Muxi; A Monegal; N Guañabens; P Peris
Journal:  Osteoporos Int       Date:  2017-06-04       Impact factor: 4.507

Review 6.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

7.  Changes in the Dickkopf-1 and tartrate-resistant acid phosphatase 5b serum levels in preschool children with nephrotic syndrome.

Authors:  Jianjiang Zhang; Huiqin Zeng; Shuqin Fu; Peipei Shi; Miao Wang; L I Guo
Journal:  Biomed Rep       Date:  2016-03-16

8.  Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.

Authors:  Jia Peng; Zhang Dong; Zhang Hui; Wang Aifei; Deng Lianfu; Xu Youjia
Journal:  BMC Musculoskelet Disord       Date:  2021-05-25       Impact factor: 2.362

9.  ERα and Wnt/β‑catenin signaling pathways are involved in angelicin‑dependent promotion of osteogenesis.

Authors:  Luna Ge; Yazhou Cui; Baoyan Liu; Xiaoli Yin; Jingxiang Pang; Jinxiang Han
Journal:  Mol Med Rep       Date:  2019-03-01       Impact factor: 2.952

10.  Epidural Spinal Cord Stimulation Facilitates Immediate Restoration of Dormant Motor and Autonomic Supraspinal Pathways after Chronic Neurologically Complete Spinal Cord Injury.

Authors:  David Darrow; David Balser; Theoden I Netoff; Andrei Krassioukov; Aaron Phillips; Ann Parr; Uzma Samadani
Journal:  J Neurotrauma       Date:  2019-03-06       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.